JACC: Basic to Translational Science最新文献

Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial. 院内PCSK9抑制对心肌梗死后心肌炎症的影响：一项随机临床试验

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-05 DOI: 10.1016/j.jacbts.2025.03.010

Efthymios Ziogos, Tarek Harb, Ines Valenta, Michael A Vavuranakis, Palmer L Foran, Marlene S Williams, Michael J Blaha, Allison G Hays, Steven R Jones, Thomas H Schindler, Steven P Schulman, Gary Gerstenblith, Thorsten M Leucker

引用次数: 0

Phenotype-Based Classification of Obstructive Hypertrophic Cardiomyopathy Undergoing Myectomy 基于表型的阻塞性肥厚型心肌病切除术分类

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2024.12.016

Hao Cui PhD , Hao Nie MD, PhD , Congrui Wang MD , Ningning Zhang MSc , Yifan Wang MD, PhD , Wendao Liu PhD , Siyuan Huang MD, PhD , Xiao Chen PhD , Hao Jia MD, PhD , Songren Shu MD, PhD , Mengxia Fu MD, PhD , Qian Zhao MSc , Xiumeng Hua MD, PhD , Yuan Chang MD, PhD , Yunhu Song MD, PhD , Jiangping Song MD, PhD

引用次数: 0

Unveiling the PGAM5-ANGPTL3 Axis 揭示PGAM5-ANGPTL3轴

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2025.02.023

Eva Hurt-Camejo PhD

引用次数: 0

β-Hydroxybutyrate Facilitates Homeostasis of Hypoxic Endothelial Cells After Myocardial Infarction via Histone Lysine β-Hydroxybutyrylation of CPT1A β-羟丁酸通过组蛋白赖氨酸β-羟丁酸化CPT1A促进心肌梗死后缺氧内皮细胞的内稳态

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2024.11.004

Zhaoyue Li MD, PhD , Yutong Guo MD , Jie Xiong MD , Liyan Bai MD , Hao Tang MD, PhD , Bo Wang MD , Bingchen Guo MD , Yi Qiu MD , Guanghui Li MD , Manyu Gong MD, PhD , Lin Lv MD, PhD , Zengxiang Dong MD, PhD , Yingfeng Tu MD, PhD

{"title":"β-Hydroxybutyrate Facilitates Homeostasis of Hypoxic Endothelial Cells After Myocardial Infarction via Histone Lysine β-Hydroxybutyrylation of CPT1A","authors":"Zhaoyue Li MD, PhD , Yutong Guo MD , Jie Xiong MD , Liyan Bai MD , Hao Tang MD, PhD , Bo Wang MD , Bingchen Guo MD , Yi Qiu MD , Guanghui Li MD , Manyu Gong MD, PhD , Lin Lv MD, PhD , Zengxiang Dong MD, PhD , Yingfeng Tu MD, PhD","doi":"10.1016/j.jacbts.2024.11.004","DOIUrl":"10.1016/j.jacbts.2024.11.004","url":null,"abstract":"<div><div>Myocardial infarction (MI) initiates a robust angiogenic response crucial for tissue repair. β-hydroxybutyrate (BHB) is an essential circulating metabolite, and its role in angiogenesis under pathological conditions remains unclear. We evaluated the coronary collateral circulation in 114 patients with MI and investigated its correlation with serum BHB levels. High BHB levels were found to correlate with better collateral circulation. Moreover, BHB promotes angiogenesis post-MI in vivo and in vitro. Mechanistically, BHB modulates the epigenetic landscape in hypoxic endothelial cells by increasing H3K9bhb levels associated with the transcriptional activation of angiogenesis-related genes and enhancing chromatin accessibility at loci associated with these genes. The integrated analysis of RNA sequencing, cleavage under targets and tagmentation, and assay for transposase-accessible chromatin with sequencing identified carnitine palmitoyltransferase 1a as a key proangiogenic target. Thus, BHB nutritional supplementation may represent a promising therapeutic strategy for ischemic heart disease, with high potential for clinical translation.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 5","pages":"Pages 588-607"},"PeriodicalIF":8.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism 最近的病理生理学见解正在推进静脉血栓栓塞的治疗

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2024.12.004

Satish Singh PhD , Pardeep Kumar MSc , Sudesh K. Yadav PhD , Farouc A. Jaffer MD, PhD , Guy L. Reed MD

{"title":"Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism","authors":"Satish Singh PhD , Pardeep Kumar MSc , Sudesh K. Yadav PhD , Farouc A. Jaffer MD, PhD , Guy L. Reed MD","doi":"10.1016/j.jacbts.2024.12.004","DOIUrl":"10.1016/j.jacbts.2024.12.004","url":null,"abstract":"<div><div>Venous thromboembolism, defined as deep vein thrombosis and pulmonary embolism, is the third leading cause of cardiovascular deaths globally. Long-term complications of unresolved venous thrombi include post-thrombotic syndrome in the legs and chronic thromboembolic pulmonary hypertension. As the venous thrombus ages, the acute, fibrin, and red blood cell-rich composition changes to a chronic cellular, fibrotic mass that does not respond to presently available therapeutic approaches. Standard anticoagulation treatment does not fully prevent recurrent thrombosis and may cause serious bleeding. Thrombolytic therapy may resolve thrombi but it has unacceptable bleeding risks. Recent drug discovery for acute venous thromboembolism has focused on novel targets that may provide enhanced safety and efficacy. Additional therapeutic strategies have focused on the transition phase of acute-to-chronic venous thromboembolism with anti-inflammatory agents, statins, and vasodilator drugs. In this review, we discuss the mechanisms of venous thrombus aging, its clinical implications, and the latest developments in pharmacotherapeutic approaches for venous thromboembolism.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 5","pages":"Pages 689-703"},"PeriodicalIF":8.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144137991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Full Issue PDF 完整版PDF

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/S2452-302X(25)00214-1

引用次数: 0

Toward a Comprehensive Understanding of Obstructive Hypertrophic Cardiomyopathy 对阻塞性肥厚性心肌病的全面认识

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2025.03.008

Ahmad Masri MD, MS

引用次数: 0

Editor’s Cut

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2025.04.002

Douglas L. Mann MD (Editor-in-Chief, JACC: Basic to Translational Science)

引用次数: 0

IL-6 Inhibitors and TNF Inhibitors IL-6抑制剂和TNF抑制剂

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2024.11.010

Simon Jønck MD, PhD , Malte Lund Adamsen MD , Iben E. Rasmussen MSc , Anna A. Lytzen MSc , Mathilde Løk BSc , Morten Asp Vonsild Lund MD , Lene Dreyer MD, PhD , Peter G. Jørgensen MD PhD , Niels Vejlstrup MD , Lars Køber MD, DMSc , Robin Christensen MSc, PhD , Søren Jacobsen MD, DMSc , Bente Klarlund Pedersen MD, DMSc , Helga Ellingsgaard MSc, PhD , Pil Højgaard MD, PhD , Ronan M.G. Berg MD, DMSc , Regitse Højgaard Christensen MD, PhD

{"title":"IL-6 Inhibitors and TNF Inhibitors","authors":"Simon Jønck MD, PhD , Malte Lund Adamsen MD , Iben E. Rasmussen MSc , Anna A. Lytzen MSc , Mathilde Løk BSc , Morten Asp Vonsild Lund MD , Lene Dreyer MD, PhD , Peter G. Jørgensen MD PhD , Niels Vejlstrup MD , Lars Køber MD, DMSc , Robin Christensen MSc, PhD , Søren Jacobsen MD, DMSc , Bente Klarlund Pedersen MD, DMSc , Helga Ellingsgaard MSc, PhD , Pil Højgaard MD, PhD , Ronan M.G. Berg MD, DMSc , Regitse Højgaard Christensen MD, PhD","doi":"10.1016/j.jacbts.2024.11.010","DOIUrl":"10.1016/j.jacbts.2024.11.010","url":null,"abstract":"<div><div>Interleukin-6 inhibitors (IL-6i) are commonly used in patients with rheumatoid arthritis to reduce inflammation from chronically increased IL-6. IL-6 levels increase transiently following exercise, exerting numerous positive effects. This study examined if beneficial exercise-induced cardiac adaptations were attenuated in patients with rheumatoid arthritis in concomitant IL-6i treatment compared with tumor necrosis factor inhibitors. Compared with control, we found that the tumor necrosis factor inhibitor–treated group, but not the IL-6i group, had a significant increase in left ventricular mass following 12 weeks of supervised exercise. However, the interaction effect of treatment modalities on exercise-induced cardiac adaptations was insignificant. (Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During IL-6 vs TNF Antibody Therapy; <span><span>NCT05215509</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 5","pages":"Pages 551-563"},"PeriodicalIF":8.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144137998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Memory of Dr Gary D. Lopaschuk, PhD (1955–2025) 纪念Gary D. Lopaschuk博士（1955-2025）。

IF 8.4 1区医学

JACC: Basic to Translational Science Pub Date : 2025-05-01 DOI: 10.1016/j.jacbts.2025.04.001

Jason R.B. Dyck PhD

引用次数: 0